Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Racestyptine is a topical hemostatic and astringent solution used in dentistry for gingival retraction and the control of capillary bleeding. Developed by Septodont, the formulation typically contains 25% aluminum chloride and oxyquinoline sulfate. Aluminum chloride acts as an astringent by precipitating tissue proteins, which causes local tissue contraction and temporary shrinkage of the gingival margin, facilitating accurate dental impressions. Oxyquinoline sulfate provides antiseptic properties to the solution. It is commonly used in conjunction with retraction cords during prosthodontic procedures to ensure clear visualization of subgingival margins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Racestyptine.